NasdaqCM - Nasdaq Real Time Price USD

BeyondSpring Inc. (BYSI)

0.6852 +0.1055 (+18.20%)

As of 11:02:20 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

GlobeNewswire 1mo ago

BYSI
+18.20%
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 2mo ago

BYSI
+18.20%
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

GlobeNewswire 5mo ago

BYSI
+18.20%
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

GlobeNewswire 5mo ago

BYSI
+18.20%
MRK
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 5mo ago

BYSI
+18.20%
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

GlobeNewswire 6mo ago

BYSI
+18.20%
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

GlobeNewswire 7mo ago

BYSI
+18.20%
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

InvestorsHub 1mo ago

BYSI
+18.20%
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

InvestorsHub 5mo ago

BYSI
+18.20%
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

Simply Wall St. 7mo ago

BYSI
+18.20%
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga 5mo ago

SLS

PSNL

WHWK
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

GlobeNewswire 5mo ago

BYSI
+18.20%

Performance Overview

Return	BYSI	S&P 500 (^GSPC)
YTD	-64.44%	+9.87%
1-Year	-69.96%	+10.08%
3-Year	-38.33%	+70.34%

U.S. markets close in 4h 51m

BeyondSpring Inc. (BYSI)

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026